Posted by Michael Wonder on 25 Mar 2017
Almirall and Sun Pharma announce regulatory filing of tildrakizumab in Europe
24 March 2017 - Almirall and Sun Pharmaceutical Industries announced today the validation of the regulatory filing of tildrakizumab with the EMA by Almirall.
Tildrakizumab is an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.
